EUVIMEDEUVIMED entdecken
Open Access

Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in gastric cancer patients receiving adjuvant oxaliplatin and capecitabine after gastrectomy: a retrospective pilot study

Wedyan Alhazmi, Kyo Young Song

Korean Journal of Clinical Oncology · 31.08.2025 · 21 (2) · 81-89

DOI: 10.14216/kjco.25349 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Korean Journal of Clinical Oncology, online erschienen am 31.08.2025. Verfasst von Wedyan Alhazmi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, King Fahad General Hospital, Jeddah, Saudi Arabia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity associated with oxaliplatin-based chemotherapy in gastric cancer patients. Recent studies suggest that high-dose intravenous selenium may exert neuroprotective effects in patients receiving platinum-based chemotherapy.

Methods

This pilot study analyzed patients with stage III gastric adenocarcinoma who underwent gastrectomy between January and December 2024. A total of 28 patients receiving adjuvant capecitabine plus oxaliplatin (XELOX) chemotherapy were included and divided into two groups: one receiving chemotherapy alone (non-selenium: n= 17) and the other receiving an intravenous injection of selenium (2,000 µg/day) before chemotherapy (selenium: n= 11). CIPN severity was assessed after the first chemotherapy cycle and at the completion of chemotherapy using standardized grading criteria.

Results

Baseline clinicopathological characteristics, including age, sex, body mass index, preoperative comorbidities, extent of resection, operation time, and hospital stay, were comparable between groups. No adverse events related to high-dose selenium administration were observed. There were no significant differences in chemotherapy-related adverse events, such as hand-foot syndrome, nausea, vomiting, diarrhea, and loss of appetite, between the two groups. While CIPN severity was similar between groups after the first chemotherapy cycle, by the end of chemotherapy, the selenium group exhibited significantly lower paresthesia severity compared to the non-selenium group (P < 0.0001).

Conclusion

High-dose intravenous selenium appears to be a safe and potentially effective intervention for reducing paresthesia associated with oxaliplatin-based chemotherapy. Further large-scale prospective studies are warranted to validate these findings and establish optimal dosing guidelines.

Schlagwörter

Stichwörter der Autor:innen

Chemotherapy-induced peripheral neuropathyGastric cancerOxaliplatinParesthesiaSelenium

Autor:innen und Institutionen

  • Department of Surgery, King Fahad General Hospital, Jeddah, Saudi Arabia.
  • Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Zitieren

APA

Alhazmi, W., & Song, K. Y. (2025). Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in gastric cancer patients receiving adjuvant oxaliplatin and capecitabine after gastrectomy: a retrospective pilot study. Korean Journal of Clinical Oncology, 21(2), 81-89. https://doi.org/10.14216/kjco.25349

Vancouver

Alhazmi W, Song KY. Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in gastric cancer patients receiving adjuvant oxaliplatin and capecitabine after gastrectomy: a retrospective pilot study. Korean Journal of Clinical Oncology. 2025;21(2):81-89. doi:10.14216/kjco.25349

BibTeX
@article{Alhazmi2025,
  author = {Alhazmi, Wedyan and Song, Kyo Young},
  title = {Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in gastric cancer patients receiving adjuvant oxaliplatin and capecitabine after gastrectomy: a retrospective pilot study},
  journal = {Korean Journal of Clinical Oncology},
  year = {2025},
  volume = {21},
  number = {2},
  pages = {81--89},
  doi = {10.14216/kjco.25349}
}
Kostenlos starten →